Goldman Sachs Maintains FibroGen(FGEN.US) With Sell Rating

Goldman Sachs analyst Paul Choi maintains $FibroGen(FGEN.US)$ with a sell rating.According to TipRanks data, the analyst has a success rate of 48.5% and a total average return of 5.1% over the past ye

Futu News03:31 · Ratings

Favourable Signals For FibroGen: Numerous Insiders Acquired Stock

Yahoo FinanceJun 18 21:02

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To

GlobeNewswireJun 18 20:00

FibroGen(FGEN.US) Officer Buys US$25,883.91 in Common Stock

$FibroGen(FGEN.US)$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.Source: Announcement What is statement of ch

Futu NewsJun 14 05:12

Pancreatic Cancer on the Rise: How Biotech Firms Are Developing Groundbreaking Treatments

After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may ...

PR NewswireJun 12 22:22

What's Going On With FibroGen Stock Tuesday?

FibroGen Inc (NASDAQ:FGEN) shares initially traded higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical t

BenzingaJun 5 02:27